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Abstract 
Purpose: The aim of the study was to investigate the incidence of and risk factors for 
hypopituitarism after gamma knife radiosurgery (GKRS) for pituitary adenoma. 
Methods: We conducted a retrospective analysis of the pituitary function of 90 patients who 
underwent GKRS for pituitary adenoma at the University Hospital Centre Zagreb between 
2003 and 2014. Twenty seven of them met the inclusion criteria and the others were excluded 
from the study due to pituitary insufficiency which was present before GKRS. Eighteen 
patients had non-functioning and 9 patients had secretory adenomas. Median patients’ age 
was 56 years (24-82). GKRS was performed using the Leksell gamma knife Model C. The 
median prescription radiation dose was 20 Gy (15-25) and the median tumor volume size was 
3.4 cm
3
 (0.06-16.81). New onset hypopituitarism was defined as a new deficit of one of the 
three hormonal axes (corticotroph, thyreotroph or gonadotroph) ≥3 months following GKRS. 
SPSS was used for statistical analysis, with the significance level at P<0.05. 
Results: During the median follow-up period of 72 months (range 6-144), 30% of patients 
developed new hypopituitarism after GKRS. This corresponds to incidence of one new case 
of hypopituitarism per 15 patient-years. The median time for the development of the first 
pituitary axis insufficiency was 41.5 months (range 3-96). Age, gender, tumor function, tumor 
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volume or prescription dose of radiation were not predictive factors for the development of 
hypopituitarism. 
Conclusions: In our cohort of patients with pituitary tumors who underwent GKRS, 30% 
developed new hypopituitarism during the follow-up period. 
Keywords: hypopituitarism, gamma knife, radiosurgery, pituitary adenoma. 
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Introduction 
Gamma knife radiosurgery (GKRS) represents the treatment of choice for patients with 
pituitary adenoma in the case of incomplete tumor resection, tumor recurrence and persistent 
hormone hypersecretion, or in those patients who, due to comorbidities, are not candidates for 
surgery [1,2].  
Hypopituitarism is one of the most common complications of GKRS. The data on its 
incidence and possible prognostic/risk factors are rather variable among studies [3-11] and 
highly dependent on the definition of endocrine dysfunction that has been used [12-15]. The 
incidence of hypopituitarism also depends on several factors, such as the type and extent of 
surgery prior to GKRS, duration of  follow-up, tumor volume, tumor function, prescription 
dose of radiation and preexisting pituitary function [4,16]. Long-term follow-up is crucial to 
assess new pituitary deficits. Typically, hypopituitarism presents within the first 2-4 years 
after the treatment with GKRS [17-19], but the risk of pituitary insufficiency increases to up 
to 80% after 10-15 years [20,21]. Reports on the highest incidence of new onset 
hypopituitarism also mentioned the longest follow-up period [22]. Long-term studies on the 
complications of GKRS are scarce. 
This paper reports on our 12-year experience in performing GKRS in patients with pituitary 
adenomas. The aim of the study was to assess the incidence and time of occurrence of new 
onset hypopituitarism after GKRS performed for pituitary adenoma as well as to analyze 
possible prognostic/risk factors associated with the development of new onset pituitary 
deficits. 
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Materials and methods 
Study design, selection criteria and subjects 
This retrospective study investigated 90 patients with pituitary adenoma who were treated 
with GKRS at the Centre for Neuroendocrinology, University Hospital Centre Zagreb, 
Croatia, between 2003 and 2014.  Sixty-three out of 90 patients had complete pituitary 
hormone insufficiency before GKRS and were therefore not included in the study. Twenty 
seven patients with at least one preserved pituitary hormone axis before GKRS and the 
minimum follow-up period of 6 months after GKRS, were enrolled in the study. The study 
was approved by the Ethics Committee of the University Hospital Center Zagreb.   
Radiotherapeutic application 
GKRS was performed using the Leksell Gamma knife Model C. Magnetic resonance imaging 
(MRI) with a stereotactic head frame was used when planning the treatment of each case. The 
radiation prescription dose to the target volume varied from 15 to 25 Gy at 50% isodose. This 
depended on the tumor volume size, distance to the optic apparatus and tumor functionality 
(secretory adenomas received higher doses of radiation). 
Evaluation of the follow-up data 
Pituitary function assessment and radiological evaluation were performed at baseline, three 
months after GKRS and then yearly afterwards. In the assessment of pituitary function, three 
hormonal axes were evaluated for each patient, i.e. the hypothalamic-pituitary-adrenal axis, 
the hypothalamic-pituitary-thyroid axis, and the hypothalamic-pituitary-gonadal axis. The 
low-dose short ACTH test (1 mcg) and/or the test of insulin-induced hypoglycemia were used 
for the evaluation of the hypothalamic-pituitary-adrenal axis. The cortisol level <550 nmol/L 
was diagnostic for the corticotroph cell insufficiency. Low fT4 level, accompanied by an 
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inappropriately low/normal TSH level were diagnostic for the hypothalamic-pituitary-thyroid 
axis insufficiency. Low testosterone levels in males, amenorrhea in premenopausal women, 
and inappropriately low/normal FSH and LH levels in postmenopausal women indicated the 
hypothalamic-pituitary-gonadal axis insufficiency. Somatotroph cell function was tested only 
in patients in whom growth hormone replacement therapy was planned (n=8). Due to the low 
number of such patients, those results were not reported in the manuscript.  
New onset hypopituitarism was defined as a new deficit of one of the hormonal axes in the 
period of at least 3 months after GKRS. Ten patients (37%) had partial pituitary hormone 
deficiency prior to GKRS with the total of 15 insufficient pituitary hormone axes. Six patients 
had corticotroph deficiency, 4 thyreotroph deficiency and 5 gonadotroph cell deficiency. 
Accordingly, a total of 66 pituitary hormone axes were available for this study. 
Statistical analysis 
Statistical analysis was done using Statistical Package for the Social Sciences (SPSS) ver. 
17.0 for Windows. Variables were described as median (range). The difference between two 
independent numerical variables was tested using the Mann-Whitney U test and between two 
categorical variables using the χ2 test. Pituitary axis event curves using the Kaplan-Meier 
method were performed.  If insufficiencies of multiple axes were found in the same patient, 
the first axis insufficiency was used for the event curve analysis. Significance level was set at 
P<0.05. 
 
Results 
The patients’ characteristics are summarized in Table 1. There were 18 clinically non-
functioning adenomas (66%): 12 null-cell adenomas, 3 silent gonadotropinomas, 2 silent 
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corticotropinomas and one silent plurihormonal (GH+PRL+TSH) adenoma. Of the 9 secreting 
adenomas, there were 6 patients with acromegaly, 2 patients with Cushing’s disease and one 
patient with prolactinoma. The median patient age at the time of GKRS was 49 years (23-74 
years) while the median age at the study data collection was 56 years (24-82 years). Fifteen 
patients (55%) were males. The median follow-up period was 72 months (6-144 months). 
The median tumor volume size was 3.41 cm
3
 (0.06-16.81), whereas the median margin dose 
of radiation was 20 Gy (15-25). There was a significantly larger median tumor volume in 
clinically non-functioning adenomas, 4.73 cm
3
 (0.06-16.81), compared to the median tumor 
volume of 1.1 cm
3
 (0.1-5.02) in the secretory adenomas, P=0.014, z=-2.469. The median 
margin dose of radiation was significantly higher in the secretory adenomas (24 Gy (15-25 
Gy)) than in the clinically non-functioning adenomas (19.5 Gy (18-23)), (P=0.046, z=-1.993).  
Before GKRS, in the study group of 27 patients, there were 66 preserved pituitary hormone 
axes. At the end of the follow-up, 8 out of 27 patients (30%) developed insufficiency of 9 
hormone axes.  Insufficiency of one hormone axis was found in seven patients, and one 
patient (no. 15
0
) developed insufficiency of two hormone axes (after 25 and 31 months). 
Altogether we observed 9/66 of new pituitary deficits during follow-up, which equals one 
new pituitary axis deficiency per 15 patient-years. 
Four out of 21 patients with normal corticotroph cell function prior to GKRS developed 
corticotroph insufficiency (19%), two out of 24 patients with normal thyreotroph cell function 
prior to GKRS developed thyreotroph insufficiency (8%), whereas three out of 22 patients 
with normal gonadotroph cell function prior to GKRS developed gonadotroph cell 
insufficiency (14%). The median time to the occurrence of the first hormone insufficiency 
was 41.5 months (3-96 months).  
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The total cumulative incidence of new onset hypopituitarism was 42%, whereas the 
cumulative incidence during the first 2 years after GKRS was 13%, as shown by the Kaplan-
Meier analysis (Figure 1.). 
No correlations were found between the prevalence of new onset pituitary insufficiency on the 
one side,  and age at GKRS, gender, tumor function, tumor type, preexisting pituitary 
function, duration of follow-up, tumor volume or the dose of radiation on the other (Table 2.).  
 
Discussion  
Hypopituitarism is the most prevalent complication of GKRS [3]. The reported incidence of 
pituitary insufficiency is highly heterogeneous across studies and it ranges between 11.6 and 
39% depending mainly on the duration of follow-up [7,9,23,24]. For example, the study with 
one of the longest follow-up periods published by Gopalan et al. [7] reported the greatest 
incidence of new pituitary deficits after GKRS for non-functioning pituitary adenoma (39%).  
In our study we found 30% patients with new endocrine deficits after GKRS, after the median 
follow-up of 72 months. A number of factors have been evaluated in order to assess the risk 
of hypopituitarism after GKRS.  The studies published so far showed that the prescription 
dose of radiation and the tumor volume size are major risk factors for new pituitary hormone 
insufficiency [25,26]. It was shown that the 5-year risk of developing new pituitary deficits 
was higher for tumors with a volume higher than 4 cm
3
 (58% vs 18%) [16]. The most recent 
systematic review and meta-analysis which included 925 patients from 17 studies showed that 
patients with non-functioning pituitary adenomas and tumor volume size >4 ml were 
associated with 22% of GKRS induced hormonal deficits, significantly higher compared to 
the patients with tumor volume size <4 ml [27]. In our study, 12/27 patients (44%) had tumor 
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volume size >4 ml, which could explain the relatively high incidence of new onset 
hypopituitarism. 
Functionality of the tumor has also been shown to play an important role in the development 
of hypopituitarism [4,16]. Numerous studies which examined functional adenomas reported 
higher incidence of new onset hypopituitarism in the group of patients with functional 
adenoma when compared to non-functioning pituitary adenomas. The incidence of 
hypopituitarism was 42% in prolactinoma [28], 50% in growth hormone secreting adenoma 
[29] and 66% in adrenocorticotropic secreting adenoma [30], with the median follow-up 
period of 60, 114 and 204 months, respectively. Another comprehensive review, which 
included 12 studies with non-functioning adenomas, 17 studies with prolactinomas, 26 studies 
with acromegaly and 17 studies with Cushing’s disease, showed variable incidence of new 
onset pituitary deficits of 0-38%, 0-42%, 0-50% and 0-66%, respectively [22]. In our study, 
we did not find significantly higher incidence of pituitary insufficiency after GKRS in the 
group of functional adenomas. That result might be explained by the relatively large volumes 
of the clinically non-functioning adenomas enrolled in the study requiring relatively high 
radiation doses. 
With regard to the timing of the development of hypopituitarism, it has been reported that 
pituitary insufficiency after GKRS may develop as early as after three months, but it also 
sometimes  develops  after as long as  10 years of follow-up [20,21]. One study reported the 
median period of 48 months from GKRS to the development of new onset hypopituitarism, 
with the first pituitary insufficiency occurring 14 months after GKRS and the last one 84 
months after GKRS [23]. In our study, the median time from GKRS to the development of the 
first hormone insufficiency was 41.5 months. The period between GKRS and the 
development of the pituitary insufficiency ranged from 3 months to 96 months. The 
10 
 
cumulative incidence of developing new onset pituitary insufficiency during the first 2 years 
after GKRS in our study was 13%.  
The major strength of our study is based on the fact that all the patients were followed-up in 
the same tertiary center with the standardized medical protocol. On the other side, the small 
sample size and a rather heterogeneous group of patients in terms of the size and tumor 
functionality represent major study limitations. Another limitation may be the lack of the data 
on somatotroph cell function, which was evaluated only in few patients and was therefore not 
reported in the manuscript. 
In conclusion, in our cohort of the patients with pituitary tumors who underwent GKRS, 30% 
of them developed new hypopituitarism, which corresponds to the incidence of one new 
hypopituitarism per 15 patient-years. The first pituitary hormone insufficiency could appear 
as soon as 3 months after GKRS and the last after many years of follow-up. Neither the tumor 
size nor the radiation dose were prognostic factors for the development of hypopituitarism 
after GKRS in our study group. Further studies with a larger number of patients stratified by 
tumor volume, tumor function and radiation dosage are needed to address this issue.  
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Figure Legends 
 
Figure 1. The incidence of new onset hypopituitarism after gamma knife radiosurgery 
(GKRS) for pituitary adenoma (Kaplan-Meier analysis). 
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Tables 
Table 1. Patients’ characteristics. 
Cas
e 
no. 
Age 
(year
s) 
Sex Tumor 
functio
n 
Tumor type Hypopituitari
sm before GK 
Follow-
up 
period 
(month
s) 
Prescripti
on dose 
(Gy) 
Tumo
r 
volu
me 
(cm
3
) 
Time to 
the first 
insufficien
cy 
(months) 
1 57 Femal
e 
Secreto
ry 
Acromegaly Corticotroph+ 
thyreotroph 
144 20 0.6 None 
2 46 Male Secreto
ry 
Acromegaly Corticotroph 
+gonadotroph 
144 15 2.2 None 
3 53 Femal
e 
NF Null-cell 
adenoma 
No 122 18 0.7 None 
4 54 Femal
e 
NF Null-cell 
adenoma 
No 122 18 0.06 96 
5 55 Femal
e 
NF Null-cell 
adenoma 
No 108 18 4.29 None 
6 49 Male Secreto
ry 
Acromegaly Corticotroph 108 16 3.4 None 
7 47 Femal
e 
Secreto
ry 
Prolactinoma No 96 25 0.99 12 
8 75 Male NF Null-cell 
adenoma 
No 96 20 0.9 None 
9 82 Male NF Null-cell 
adenoma 
No 96 19 2.17 36 
10 59 Male NF Silent 
gonadotropino
ma 
No 96 23 2.5 None 
17 
 
11 66 Femal
e 
Secreto
ry 
Cushing 
disease 
Corticotroph 90 25 0.1 None 
12 80 Male NF Null-cell 
adenoma 
No 80 22 3.35 None 
13 73 Male NF Null-cell 
adenoma 
Thyreotroph+ 
gonadotroph 
72 18 8.94 60 
14 46 Femal
e 
NF Silent 
corticotropino
ma 
No 72 18 16.81 None 
15 80 Femal
e 
NF Null-cell 
adenoma 
No 69 20 6.8 25 and 31 
16 61 Male NF Silent 
gonadotropino
ma 
No 65 22 5.59 None 
17 41 Male NF Null-cell 
adenoma 
Corticotroph + 
thyreotroph 
61 18 4.82 61 
18 32 Femal
e 
Secreto
ry 
Acromegaly Thyreotroph 48 25 5.02 47 
19 75 Male NF Silent 
gonadotropino
ma 
Gonadotroph 28 22 5.47 None 
20 64 Male NF Null-cell 
adenoma 
No 27 22 3.61 None 
21 66 Male NF Silent 
corticotropino
ma 
Corticotroph + 
gonadotroph 
25 18 9.4 None 
22 47 Femal
e 
NF Null-cell 
adenoma 
Gonadotroph 21 20 5.38 None 
23 50 Femal Secreto Cushing No 14 24 1.5 None 
18 
 
e ry disease 
24 56 Male NF Null-cell 
adenoma 
No 12 18 6.13 None 
25 56 Femal
e 
Secreto
ry 
Acromegaly No 11 25 0.75 None 
26 65 Male NF Silent 
plurihormonal 
(GH+PRL+TS
H) 
No 8 20 4.64 None 
27 24 Male Secreto
ry 
Acromegaly No 6 24 1.1 3 
*
GK= gamma knife, NF= non-functioning, GH= growth hormone, PRL= prolactinoma, TSH= thyroid-
stimulating hormone. 
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Table 2. Influence of different prognostic factors on new onset pituitary insufficiency. 
Prognostic factor New onset insufficiency No insufficiency P Z or χ2 
Age at GKRS (years) 40.5 (23-74) 53 (34-73) 0.457 -0.744 
Sex (m/f) 4/4 11/8 0.706 0.142 
Tumor function (yes/no) 3/5 6/13 0.766 0.089 
Tumor type 
  Non-functioning (n=18) 
  Cushing disease (n=2) 
  Acromegaly (n=6) 
  Prolactinoma (n=1) 
 
5 
0 
2 
1 
 
13 
2 
4 
0 
0.35 3.286 
Hypopituitarism before GKRS 
(yes/no) 
3/5 7/12 0.974 0.001 
Follow-up period (months) 70.5 (6-122) 72 (8-144) 0.958 -0.053 
Tumor volume (cm
3
) 3.5 (0.06-8.94) 3.4 (0.1-16.81) 1 0 
Margin dose of radiation (Gy) 19.5 (18-25) 20 (15-25) 0.745 -0.325 
*
Z value where Mann-Whitney U test was performed for and χ2 value where χ2 test was performed. P value 
<0.05 was considered statistically significant. 
†
GKRS= gamma knife radiosurgery. 
 
 
 
 
